Alpha 2.0
Login Register
» Articles » PMID: 15557656

Use of Translational Fusion of the MrpH Fimbrial Adhesin-binding Domain with the Cholera Toxin A2 Domain, Coexpressed with the Cholera Toxin B Subunit, As an Intranasal Vaccine to Prevent Experimental Urinary Tract Infection by Proteus Mirabilis

Overview
Journal Infect Immun
Publisher American Society for Microbiology
Specialty Allergy & Immunology
Date 2004 Nov 24
PMID 15557656
Citations 24
Authors
Xin Li
Jarrod L Erbe
C Virginia Lockatell
David E Johnson
Michael G Jobling
Randall K Holmes
Harry L T Mobley
Affiliations
Soon will be listed here.
Abstract

This is a follow-up to our previous study using an intranasal vaccine composed of MrpH, the tip adhesin of the MR/P fimbria, and cholera toxin to prevent urinary tract infection by Proteus mirabilis (X. Li, C. V. Lockatell, D. E. Johnson, M. C. Lane, J. W. Warren, and H. L. Mobley, Infect. Immun. 72:66-75, 2004). Here, we have expressed a cholera toxin-like chimera in which the MrpH adhesin-binding domain (residues 23 to 157) replaces the cholera toxin A1 ADP-ribosyltransferase domain. This chimera, when administered intranasally without additional adjuvant, is sufficient to induce protective immunity in mice.

Citing Articles

In-Depth Characterization of a Re-Engineered Cholera Toxin Manufacturing Process Using Growth-Decoupled Production in .

Danielewicz N, Dai W, Rosato F, Webb M, Striedner G, Romer W Toxins (Basel). 2022; 14(6).

PMID: 35737057 PMC: 9228256. DOI: 10.3390/toxins14060396.

Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.

Swietnicki W Biomolecules. 2021; 11(6).

PMID: 34203937 PMC: 8232601. DOI: 10.3390/biom11060892.

Natural therapeutics for urinary tract infections-a review.

Das S Futur J Pharm Sci. 2020; 6(1):64.

PMID: 33215041 PMC: 7498302. DOI: 10.1186/s43094-020-00086-2.

Biochemical and immunological characterization of an ETEC CFA/I adhesin cholera toxin B subunit chimera.

Jobling M, Poole S, Rasulova-Lewis F, ODowd A, McVeigh A, Balakrishnan A PLoS One. 2020; 15(3):e0230138.

PMID: 32176708 PMC: 7075575. DOI: 10.1371/journal.pone.0230138.

Immunogenicity of a Staphylococcus aureus-cholera toxin A/B vaccine for bovine mastitis.

Misra N, Wines T, Knopp C, Hermann R, Bond L, Mitchell B Vaccine. 2018; 36(24):3513-3521.

PMID: 29739718 PMC: 6014625. DOI: 10.1016/j.vaccine.2018.04.067.

References
1.
Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, Holmgren J . Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect Immun. 2000; 68(10):5749-55. PMC: 101533. DOI: 10.1128/IAI.68.10.5749-5755.2000. View
2.
Jobling M, Holmes R . Biological and biochemical characterization of variant A subunits of cholera toxin constructed by site-directed mutagenesis. J Bacteriol. 2001; 183(13):4024-32. PMC: 95286. DOI: 10.1128/JB.183.13.4024-4032.2001. View
3.
Li X, Lockatell C, Johnson D, Mobley H . Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis. Mol Microbiol. 2002; 45(3):865-74. DOI: 10.1046/j.1365-2958.2002.03067.x. View
4.
Eriksson K, Holmgren J . Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol. 2002; 14(5):666-72. DOI: 10.1016/s0952-7915(02)00384-9. View
5.
Li X, Lockatell C, Johnson D, Lane M, Warren J, Mobley H . Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infect Immun. 2003; 72(1):66-75. PMC: 343968. DOI: 10.1128/IAI.72.1.66-75.2004. View